logo
logo
  • Product
    • Cloud
    • Cluster
      • Andromeda
    • System
    • Processor
    • Software
  • Applications
    • Natural Language Processing
    • Computer Vision
    • High-Performance Computing
    • Industries
      • Health & Pharma
      • Energy
      • Government
      • Scientific Computing
      • Financial Services
      • Web and Social Media
  • Resources
    • Customer Spotlights
    • Blog
    • Publications
    • Events
    • White Papers
  • Developers
    • Community
    • Developer Blog
    • Documentation
    • Cerebras Model Zoo
    • Request Access to SDK
  • Company
    • About
    • In the News
    • Awards
    • Press Releases
    • Press Kit
  • Join Us
    • Life at Cerebras
    • All openings
  • Get Demo
  • Search
May 13, 2020
In Business, Machine Learning, Blog

Argonne National Laboratory and Cerebras Systems Leverage the World’s Fastest AI Supercomputer to Advance COVID-19 Research

In November 2019, the U.S. Department of Energy’s Argonne National Laboratory (ANL) and Cerebras Systems, a leader in artificial intelligence […]

Photo Credit: Argonne National Lab

In November 2019, the U.S. Department of Energy’s Argonne National Laboratory (ANL) and Cerebras Systems, a leader in artificial intelligence (AI) compute, announced a partnership to explore how deep learning can advance research in cancer, traumatic brain injury and the properties of black holes, amongst other areas, using Cerebras’ industry-leading CS-1 system. When COVID-19 reached pandemic status in March 2020, however, ANL quickly pivoted their research to help in the race to find life-saving treatments and therapeutics.

Inventing a new drug, obtaining regulatory approvals, and reaching commercialization generally takes decades. A faster alternative to finding a therapeutic for COVID-19 is to reuse drugs that are already approved for use in humans. The problem then becomes determining which existing drug will be effective in the fight against coronavirus – that is, which molecules from already-approved drugs can best bind to the docking sites of the virus’ proteins to inhibit them from attaching to human host cells.

The first step in rendering the virus inactive is to identify which of the candidate molecules from existing approved drugs can bind to the pockets of the COVID-19 virus’ proteins and block its docking sites. Historically, the way to tackle this challenge was through brute-force computation. Each molecule would be computed a “docking score” based on its characteristics or descriptors, which ends up being a very compute-intensive task given there are billions of molecules, and each of the virus’ proteins have dozens of docking sites. 

ANL took a different approach, leveraging the power of AI and machine learning (ML) to develop a model which much more efficiently processes ANL’s massive datasets to determine which molecules have the best docking scores. This ML model allows ANL to quickly predict which drug molecules are the best candidates for the next stage of testing. Instead of employing brute force computation, which would take substantially more time and require significantly more computing power, ANL used the full force of its supercomputing infrastructure and state-of-the-art AI technology, including the Cerebras CS-1 system. 

The CS-1, introduced in November 2019, was designed to solve these types of challenges by delivering record-breaking performance and scale to AI compute. ANL is using the CS-1 to train the models which predict docking scores. The speed in turnaround is allowing the team to churn through the massive datasets much more quickly, enabling faster experimentation at a time when the problem is urgent and the potential exploration space is enormous.

ANL and Cerebras are collaborating on training a second model which uses an image-based representation rather than a numerical representation of the molecular characteristics, and has, in testing, yielded excellent model results. By using image-based representations of the drug molecules and virus proteins, ANL can train the CS-1 to learn using the same “language” that chemists use to communicate about molecules – diagrams that detail molecular structure and shape.

Once the CS-1 is running the ML models, the next step is to run inference over several billion samples to pick the ones most likely to bind to the virus’ pocket and prevent it from binding to other host cells. From there, ANL is building in-silico models to understand the interactions of the selected drug molecules further. Finally, the most promising drug candidates are passed to the wet-lab for verification. This enables drug development facilities to test only the most viable drug molecules, saving valuable time and resources.

Just weeks after testing has begun, the collaboration and results have already been very promising. By using the CS-1, ANL can train models hundreds of times faster than before, enabling them to quickly identify which drug molecules will be most effective in binding to the virus’ proteins and keeping the Pandora’s Box of COVID-19 closed. In the war against COVID-19 and other novel viruses, the power of AI supercomputers promises to build more robust workflows, accelerate research and development of deep learnings models and greatly advance the future of disease research. 


Ugnius
Author posts
Related Posts
ChipMachine LearningSoftwareClusterSDKBlogHPCDeveloper Blog

February 16, 2023

Cerebras Announces Fine-Tuning on the Cerebras AI Model Studio

Announcing the addition of fine-tuning capabilities for large language models…


Avatar photoby Udai Mody

Machine LearningSoftwareSDKBlogHPCDeveloper Blog

February 15, 2023

What’s New in R0.6 of the Cerebras SDK

The latest release of our SDK includes a host of new features to improve…


Avatar photoby Leighton Wilson

ChipMachine LearningSoftwareClusterBlogComputer Vision

February 13, 2023

Unlocking High-Resolution Computer Vision with Wafer-Scale Technology

We have built a platform for accelerating CV workloads that allows users to…


Avatar photoby Manikandan Ananth

Add comment Cancel reply

You must be logged in to post a comment.

  • Prev
  • Next

Explore more ideas in less time. Reduce the cost of curiosity.

Sign up

info@cerebras.net

1237 E. Arques Ave
Sunnyvale, CA 94085

Follow

Product

Cluster
System
Chip
Software
Cloud

Applications

Natural Language Processing

Computer Vision

High Performance Computing

Industries

Health & Pharma
Energy
Government
Scientific Computing
Financial Services
Web & Social Media

Resources

Customer Spotlight
Blog
Publications
Event Replays
Whitepapers

Developers

Community
Developer Blog
Documentation
ML Public Repository
Request Access to SDK

Company

About Cerebras
In the News
Press Releases
Privacy
Legal
Careers
Contact

© 2023 Cerebras. All rights reserved

Privacy Preference Center

Privacy Preferences

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}